BR112015011756A2 - inibidores da glutamase e métodos de uso - Google Patents

inibidores da glutamase e métodos de uso

Info

Publication number
BR112015011756A2
BR112015011756A2 BR112015011756A BR112015011756A BR112015011756A2 BR 112015011756 A2 BR112015011756 A2 BR 112015011756A2 BR 112015011756 A BR112015011756 A BR 112015011756A BR 112015011756 A BR112015011756 A BR 112015011756A BR 112015011756 A2 BR112015011756 A2 BR 112015011756A2
Authority
BR
Brazil
Prior art keywords
methods
glutamase
inhibitors
compounds
inhibit glutaminase
Prior art date
Application number
BR112015011756A
Other languages
English (en)
Inventor
G Salituro Francesco
Popovici-Muller Janeta
O Saunders Jeffrey
Travins Jeremy
M Lemieux Rene
Yan Shunqi
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of BR112015011756A2 publication Critical patent/BR112015011756A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)

Abstract

resumo “inibidores da glutamase e métodos de uso” compostos e composições compreendendo compostos que inibem a glutaminase são aqui descritos. são também aqui descritos métodos de uso de compostos que inibem a glutaminase no tratamento do câncer.
BR112015011756A 2012-11-21 2013-11-21 inibidores da glutamase e métodos de uso BR112015011756A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729321P 2012-11-21 2012-11-21
PCT/US2013/071212 WO2014081925A1 (en) 2012-11-21 2013-11-21 Glutamase inhibitors and method of use

Publications (1)

Publication Number Publication Date
BR112015011756A2 true BR112015011756A2 (pt) 2017-07-11

Family

ID=49780330

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011756A BR112015011756A2 (pt) 2012-11-21 2013-11-21 inibidores da glutamase e métodos de uso

Country Status (15)

Country Link
US (3) US9303002B2 (pt)
EP (1) EP2922832B1 (pt)
JP (1) JP6333280B2 (pt)
KR (1) KR20150085078A (pt)
CN (1) CN105263915B (pt)
AU (2) AU2013347933C1 (pt)
BR (1) BR112015011756A2 (pt)
CA (1) CA2892089A1 (pt)
EA (1) EA029531B1 (pt)
ES (1) ES2761951T3 (pt)
HK (1) HK1213889A1 (pt)
IL (1) IL238959A (pt)
MX (1) MX369691B (pt)
SG (1) SG11201504022RA (pt)
WO (1) WO2014081925A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104622790A (zh) 2010-11-01 2015-05-20 普西维达公司 用于递送治疗剂的可生物侵蚀的硅基装置
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EA029707B1 (ru) 2012-11-16 2018-05-31 Калитера Байосайенсиз, Инк. Гетероциклические ингибиторы глютаминазы
CA2892089A1 (en) * 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
EA033163B1 (ru) 2014-01-06 2019-09-30 Ризен Фармасьютикалз Са Ингибиторы глутаминазы
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use
MA49708A (fr) 2014-04-30 2020-06-03 Pfizer Dérivés de dihétérocycle liés à cycloalkyle
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
EA036001B1 (ru) 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
SI3164394T1 (sl) * 2014-07-03 2020-08-31 Board Of Regents, The University Of Texas System GLS1 inhibitorji za zdravljenje bolezni
US10660861B2 (en) 2014-07-09 2020-05-26 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
JP2017523211A (ja) 2014-08-04 2017-08-17 ドレクセル ユニバーシティ 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法
EP3193876B1 (en) 2014-08-07 2022-01-12 Calithera Biosciences Inc. Crystal forms of glutaminase inhibitors
MX2017012408A (es) * 2015-03-30 2018-04-26 Calithera Biosciences Inc Metodos para administrar inhibidores de glutaminasa.
US10441587B2 (en) 2015-04-06 2019-10-15 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
EP3316887B1 (en) 2015-06-30 2020-04-08 Board of Regents, The University of Texas System Gls1 inhibitors for treating disease
SG11201802830QA (en) 2015-10-05 2018-05-30 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors and immuno-oncology agents
RU2018124266A (ru) 2015-12-22 2020-01-23 Боард Оф Реджентс, Де Юниверсити Оф Техас Систем Солевые формы и полиморфы (R)-1-(4-(6-(2-(4-(3,3-дифторциклобутокси)-6-метилпиридин-2-ил)ацетамидо)пиридазин-3-ил)-2- фторбутил) -N-метил-1Н-1,2,3-триазол-4-карбоксамид
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
EA201990567A1 (ru) 2016-08-25 2019-08-30 Калитера Байосайенсиз, Инк. Комбинированная терапия с ингибиторами глутаминазы
CN107137401A (zh) * 2017-03-28 2017-09-08 刘纪君 一种治疗产后抑郁症的药物组合物
JP7361687B2 (ja) 2017-10-18 2023-10-16 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム グルタミナーゼ阻害薬療法
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) * 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DK0691962T3 (da) 1993-03-29 2000-10-16 Basf Ag 1-amino-3-phenoxypropanderivater som modulatorer ved multilægemiddelresistens
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
ES2237919T4 (es) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20030054985A1 (en) 2000-02-22 2003-03-20 Stuart Aaronson N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
ATE261126T1 (de) 2002-08-01 2004-03-15 Mtm Lab Ag Verfahren für lösung-basierte diagnose
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
DE602006016085D1 (de) 2005-03-16 2010-09-23 Genentech Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
CA2702462A1 (en) 2007-11-19 2009-05-28 Genentech, Inc. Compositions and methods for inhibiting tumor progression
US7951549B2 (en) 2008-03-07 2011-05-31 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
WO2010120966A1 (en) 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
EP2585833B1 (en) 2010-06-23 2017-05-31 University of Louisville Research Foundation, Inc. Methods for detecting cancer
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN104220090A (zh) * 2011-09-20 2014-12-17 淡马锡生命科学实验室有限公司 肠道病毒71型的特异性抗体及其用途
EA026656B1 (ru) * 2011-11-21 2017-05-31 Калитера Байосайенсиз Инк. Гетероциклические ингибиторы глютаминазы
EP2844270A4 (en) 2012-03-15 2016-01-27 Univ New York State Res Found POLYTHERAPIES INCLUDING EXTRACELLULAR DOMAIN INHIBITORS OF E-CADHERHINE
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
WO2014138391A1 (en) 2013-03-06 2014-09-12 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
EA033163B1 (ru) 2014-01-06 2019-09-30 Ризен Фармасьютикалз Са Ингибиторы глутаминазы
AU2015231053B2 (en) 2014-03-21 2019-04-11 Les Laboratoires Servier Compounds and their methods of use

Also Published As

Publication number Publication date
IL238959A (en) 2017-12-31
US10414740B2 (en) 2019-09-17
MX369691B (es) 2019-11-19
CA2892089A1 (en) 2014-05-30
CN105263915A (zh) 2016-01-20
ES2761951T3 (es) 2020-05-21
EP2922832A1 (en) 2015-09-30
IL238959A0 (en) 2015-07-30
EA029531B1 (ru) 2018-04-30
WO2014081925A1 (en) 2014-05-30
EP2922832B1 (en) 2019-10-09
MX2015006478A (es) 2015-12-03
JP2016500107A (ja) 2016-01-07
US20150299152A1 (en) 2015-10-22
SG11201504022RA (en) 2015-06-29
US9303002B2 (en) 2016-04-05
HK1213889A1 (zh) 2016-07-15
US10011574B2 (en) 2018-07-03
US20140142146A1 (en) 2014-05-22
KR20150085078A (ko) 2015-07-22
AU2013347933C1 (en) 2018-10-04
AU2013347933B2 (en) 2018-03-29
AU2013347933A1 (en) 2015-06-11
EA201590997A1 (ru) 2015-11-30
AU2013347933A2 (en) 2015-07-09
AU2018204692A1 (en) 2018-07-19
CN105263915B (zh) 2019-04-12
US20180370930A1 (en) 2018-12-27
JP6333280B2 (ja) 2018-05-30

Similar Documents

Publication Publication Date Title
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
BR112015011830A2 (pt) compostos e seus métodos de utilização
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20150462A (es) Inhibidores de erk y sus usos
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
MX2015004771A (es) Metodos para tratar cancer.
EA201400178A1 (ru) Лечение рака молочной железы
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CR20140367A (es) Inhibidores de iap
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25G Requested change of headquarter approved

Owner name: AGIOS PHARMACEUTICALS, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements